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ABSTRACT: Direct infusion high-resolution mass spectrometry (DIHRMS) is a
novel, high-throughput approach to rapidly and accurately profile hundreds of
lipids in human serum without prior chromatography, facilitating in-depth lipid
phenotyping for large epidemiological studies to reveal the detailed associations of
individual lipids with coronary heart disease (CHD) risk factors. Intact lipid
profiling by DIHRMS was performed on 5662 serum samples from healthy
participants in the Pakistan Risk of Myocardial Infarction Study (PROMIS). We
developed a novel semi-targeted peak-picking algorithm to detect mass-to-charge
ratios in positive and negative ionization modes. We analyzed lipid partial
correlations, assessed the association of lipid principal components with
established CHD risk factors and genetic variants, and examined differences
between lipids for a common genetic polymorphism. The DIHRMS method
provided information on 360 lipids (including fatty acyls, glycerolipids,
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glycerophospholipids, sphingolipids, and sterol lipids), with a median coefficient of variation of 11.6% (range: 5.4−51.9). The
lipids were highly correlated and exhibited a range of associations with clinical chemistry biomarkers and lifestyle factors. This
platform can provide many novel insights into the effects of physiology and lifestyle on lipid metabolism, genetic determinants
of lipids, and the relationship between individual lipids and CHD risk factors.
KEYWORDS: lipidomics, mass spectrometry, protocol, genetics, coronary heart disease
■ INTRODUCTION
Lipids have many different functions, from membrane
components to cell signaling, and are associated with a number
of chronic diseases, including coronary heart disease (CHD).1−4
Atherosclerosis, the main cause of CHD, is associated with lipid
accumulation and aggregation, particularly of cholesterol and its
derivatives. Furthermore, excess energy intake can lead to
hyperlipidemia, a major risk factor for CHD. Many genetic
polymorphisms at genes involved in lipid metabolism and lipid
circulation are associated with CHD risk.5,6 Improving our
understanding of the mechanisms that underlie these associa-
tions will facilitate the development of pharmacological
interventions to reduce the risk and burden of CHD and other
chronic diseases.
The development of new analytical technologies for the
analysis of lipids, particularly in mass spectrometry and data
processing,7 has led to the rise of lipidomics,8 with the aim of
capturing information on a wide range of lipids in a given
biological sample, across a large number of individuals.1 In
particular, lipidomic analysis of human blood has the potential to
identify the role of specific lipids in diseases, including CHD.3
There are important prerequisites for any method that uses
profiles of serum lipids to study lipid metabolism. Since by
definition an open-profiling method does not target particular
lipids, it must have the ability tomeasure and discriminate a wide
range of lipids with minimal bias across different lipid species
and classes.9
This study provides a detailed description of the method used
for a large-scale lipidomics analysis in 5662 healthy participants
in the Pakistan Risk of Myocardial Infarction Study
(PROMIS),10 which is currently among the largest MS-based
metabolomics studies. While the vast majority of metabolomics
studies have focused onWestern populations, our study is one of
the first to profile lipid levels in a Pakistani population. Chronic
diseases in Pakistan are responsible for 50% of the total disease
burden,11 and ischemic heart disease and stroke are among the
top ten causes of years of life lost.12
Our newly developed method uses direct nanospray-infusion
coupled to high-resolution mass spectrometry (DIHRMS),
which yielded the intensities of several thousand features.
Although the platform itself is nontargeted and measures all
signals within a specified mass-to-charge ratio (m/z) window,
we developed a novel peak-picking approach based on a local
database of lipid species previously detected in pooled samples,
which is scalable to large epidemiological studies, to obtain
signals for a targeted set of lipids that can reasonably be expected
from human serum.
To demonstrate the utility of the DIHRMS platform to inform
lipid research and the genetic determinants of human
metabolism, we examined levels of individual lipids associated
with rs662799, a common genetic polymorphism in the
APOA5−APOC3 gene region that is known to associate with
major lipid markers and coronary artery disease (CAD).13,14 We
chose to focus on this genetic region as it is well-known and has
been thoroughly studied, allowing us to validate the platform
and demonstrate how it can provide additional information
about the association of lipids with genetic variants. Variants in
the APOA5−APOC3 region are associated with elevated
triacylglycerol levels,14 but most studies to-date have only
looked at APOA5−APOC3 variants in relation to total
triacylglycerols. Our lipidomics platform provides details in
much higher resolution about the nature of the association of
genetic variants in this region with over 50 specific
triacylglycerol species, as well as with a wide variety of other
lipids from various lipid classes.
■ METHODS
Study Description
PROMIS is a case-control study of first-ever acute myocardial
infarction (MI) in patients from nine centers in urban Pakistan,
the details of which have been published previously.10 Controls
were individuals without a self-reported history of cardiovascular
disease (who had no ECG changes consistent with a previous
MI) drawn from individuals concurrently identified in the same
hospitals as index cases. Participants were excluded if they (1)
had previous history of cardiovascular disease; (2) had an
infection that occurred in the previous 2 weeks; (3) had
documented chronic conditions, such as malignancy, any
chronic infection, leprosy, malaria or other bacterial/parasitic
infections, chronic inflammatory disorders, hepatitis or renal
failure on past medical history; (4) were pregnant; or (5) refused
to give consent. Anthropometry measurements, including
height, weight, systolic blood pressure (SBP), and diastolic
blood pressure (DBP), were measured using standardized
procedures and equipment. Nonfasting blood samples were
drawn from each participant, centrifuged within 45 min of
venipuncture, frozen, and transported on dry ice to Cambridge,
UK, from which major lipids and other standard biomarkers
were measured (e.g., total cholesterol, low-density lipoprotein
cholesterol [LDL-C], high-density lipoprotein cholesterol
[HDL-C], total triacylglycerols, hemoglobin A1c [HbA1c],
apolipoprotein B, C-reactive protein). Samples were stored at
−80 °C until use. DNA was extracted from leukocytes in
Pakistan and genotyped at the Wellcome Trust Sanger Institute
in Cambridge, UK, on either the Illumina 660-Quad genome-
wide array or the Illumina HumanOmniExpress array. Details of
the genotyping, imputation, and quality control (QC) have been
described previously.10,15
Lipidomics Sample Selection and Batch Design
We selected 5674 PROMIS participants who had genetic data
and complete information on age, sex, ethnicity, recruitment
center, and date of survey completion. Only non-MI participants
were selected to avoid possible confounding from the metabolic
factors of patients who had recently experienced an MI. The
samples were analyzed on 72 plates, each with a maximum of 80
samples per plate, according to a randomized block design that
was developed using the “blockTools” package16 in R v3.1.2.
Sex, age, ethnicity, center, and time in years since date of survey
were used as factors in the design, and the distance between
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blocks was minimized for all factors. A QC sample was created
by pooling 100 μL of serum from 200 randomly selected
samples, which was mixed and aliquoted for use on each plate. A
subset of the QC sample was diluted with phosphate-buffered
saline solution to two different concentrations, giving three
different QC samples per plate (QC1 was undiluted, QC2 was
1:1 diluted, andQC3 was 1:3 diluted). For all samples, including
QC samples, 15 μL was aliquoted into 1.2 mL Cryovial tubes.
Lipidomics Sample Extraction
We adapted a method for open-profiling of lipids by
DIHRMS.17,18 An automated method for the extraction of
lipids was developed using an Anachem Flexus automated liquid
handler (Anachem, Milton Keynes, UK). Eighty PROMIS
samples, four blanks, and 12 QC samples in 1.2 mL Cryovials
were placed on the Flexus, 100 μL of Milli-Q H2O was added to
each of the wells and mixed, and then 100 μL of the mixture was
transferred to a glass coated 2.4 mL deep well plate (Plate+,
Esslab, Hadleigh, UK). Next, 250 μL of MeOH was added
containing six internal standards (0.6 μM 1,2-di-O-octadecyl-sn-
glycero-3-phosphocholine, 1.2 μM 1,2-di-O-phytanyl-sn-glyc-
ero-3-phosphoethanolamine, 0.6 μM C8-ceramide, 0.6 μM N-
heptadecanoyl-D-erythro-sphingosylphosporylcholine, 6.2 μM
undecanoic acid, 0.6 μM trilaurin), followed by 500 μL of
methyl tert-butyl ether (MTBE). The plates were then sealed
(using Corning aluminum microplate sealing tape [Sigma-
Aldrich Company, UK]) and shaken for 10 min at 600 rpm (4g),
after which the plate was transferred to a centrifuge and spun for
10 min at 6000 rpm (4000g). Each well in the resulting plate had
two layers, with an aqueous layer at the bottom and an organic
layer on top. A 96-head microdispenser (Hydra Matrix, Thermo
Fisher Ltd., Hemel Hampstead, UK) was used to transfer 25 μL
of the organic layer to a glass coated 240 μL low well plate
(Plate+, Esslab, Hadleigh, UK), and 90 μL of MS-mix (7.5 mM
NH4Ac IPA:MeOH [2:1]) was added using a Hydra Matrix,
after which the plate was sealed and stored at −20 °C until
analysis.
Direct Infusion High-Resolution Mass Spectrometry
All samples were infused into an Exactive Orbitrap (Thermo,
Hemel Hampstead, UK), using a Triversa Nanomate (Advion,
Ithaca, US). The Nanomate infusion mandrel was used to pierce
the seal of each well before analysis, after which, with a fresh tip,
5 μL of sample was aspirated, followed by an air gap (1.5 μL).
The tip was pressed against a fresh nozzle and the sample was
dispensed using 0.2 psi nitrogen pressure. Ionization was
achieved with a 1.2 kV voltage. The Exactive started acquiring
data 20 s after sample aspiration began. The Exactive acquired
data with a scan rate of 1 Hz (resulting in a mass resolution of
65 000 full width at half-maximum [fwhm] at 400 m/z). After
72 s of acquisition in positive mode the Nanomate and the
Exactive switched over to negative mode, decreasing the voltage
to −1.5 kV. The spray was maintained for another 66 s, after
which the analysis was stopped, and the tip was discarded before
the analysis of the next sample began. The sample plate was kept
at 15 °C throughout the analysis. Samples were run in row order
and repeated multiple times, if necessary, to ensure accuracy. A
technical description with further details of the DIHRMS
approach can be found in the Supplementary Methods
(Supporting Information).
Figure 1. Schematic of the peak-picking process. (a) XCMS was used to average 50 spectra in positive and negative ionization modes, yielding (b) the
averagemass spectrum for that particular polarity, for which signals were obtained using a peak-picking algorithm that determined the (c) peak signal at
themidpoint of a line drawn at half-height for peaks near signals that corresponded to known lipids. Signals and deviations from known lipids were then
(d) combined in a database, and separated into individual files for (e) signals and (f) deviations for each lipid.
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Lipidomics Data Processing and Peak Picking
Samples were considered poor quality if there was no signal or
the intensity of the total ion current was below 105. We repeated
259 samples that initially met these criteria until suitable signals
were obtained for all samples. Once a clean list of 96 raw files,
including blanks and QC samples, was obtained for each of the
72 plates, the files were decompressed and converted to mzXML
format using the “msconvert” tool in ProteoWizard.19 For each
infusion, an average spectrum was calculated from the user-
defined time window (Figure 1a). The “xcms” R package7 was
used to average 50 spectra per mode using an m/z window of
185−1000 and a retention time window of 20−70 s for positive
ionization mode and 95−145 s for negative ionization mode
(Figure 1b).
To identify lipids prior to data processing, the pooled sample
was analyzed on a Velos Elite Orbitrap interfacedwith an Advion
Nanomate using the previous ionization parameters. Fragmen-
tation was performed using a combination of collision-induced
disassociation (CID) and high-energy collision disassociation
(HCD) fragmentation. Fragmentation patterns were matched
using the LIPID Metabolites and Pathways Strategy (LIPID
MAPS) database.20 Peaks were identified relative to a set ofm/z
values for known lipids downloaded from the LIPID MAPS
database, and were retained if they were within a ± 5 ppm
window of the target m/z. Lipid subclasses searched in positive
ionization mode were cholesterols (Chol), cholesteryl esters
(CE), diacylglycerols (DG), triacylglycerols (TG), phosphatic
acids (PA), lysophosphosphocholines (LysoPC), phosphatidyl-
cholines (PC), phosphatidylethanolamines (PE), and sphingo-
myelins (SM). In negative ionization mode, lipid subclasses
searched were ceramides (Cer), free fatty acids (FreeFA), PA,
PC, PE, phosphatidylglycerols (PG), phosphatidylinositols
(PI), phosphatidylserines (PS), and SM. Adducts considered
were [M + H]+, [M + NH4]
+, and [M + H− 2H2O]+ in positive
ionization mode, and [M −H]− and [M + acetate]− in negative
ionization mode. Isotope labeling was assessed visually and
using the CAMERA package21 within Bioconductor and R.
Following annotation in the pooled sample a list ofm/z identity
pairs, based on expected and possible lipids identified in human
serum from the pool, was used to extract small windows of data
around the targetm/z in the average spectrum (Figure 1c). Note
that while different adducts of a lipid are identified as separate
entities, this approach focuses on the M ion rather than M + 1
andM + 2 ions, hence “deisotoping” the data by excluding these
peaks from the look-up table of identified lipid species. The peak
maximum was measured and the two closest points to the half-
height on either side were found, resulting in four points. The
points with which a horizontal line at half-height intersected a
line connecting the two points on either side of the peak (one
above the half-height and one below) was used for a peak-width
calculation (distance of the line) and a more accurate m/z value
for the peak maximum (midpoint of the line). For all m/z
identity pairs, the maximum intensity was recorded as well as the
deviation of the peaks’ accurate m/z (Figure 1d). A major
advantage of this approach is that it could be performed for each
sample independently and run in parallel. The final step was the
combination of all the signals (Figure 1e) and deviations (Figure
1f) into their respective files. The technical setup yielded average
deviations of less than 4 ppm for the detected lipid species.
Lipidomics Data Cleaning and Quality Control
The peak-picking algorithm initially selected all lipids from a list
containing 1305 lipids in positive ionization mode and 3772
lipids in negative ionization mode, corresponding to the
expected major ions of all known lipids within the m/z range
used and including all the previously identified lipid species from
the pooled sample in what we refer to as a semi-targeted
approach.22 QCwas performed to remove lipid signals that were
not reliably detectable or did not show a linear response. Lipid
signals were removed that were present in fewer than 80% of all
QC samples or that had a poor correlation with concentration
within the dilution range of QC samples (Pearson correlation r <
0.95). The coefficient of variation (CV) for each lipid signal was
then determined and all lipids with CVs of more than 25% were
omitted.
For each sample, the sum of the signals of all lipids within each
ionization mode that passed the QC steps was calculated.
Participants were excluded from analysis in a particular
ionization mode if the total signal for the lipids in that mode
was less than 5 000 000 (relative units), signifying poor infusion
of the sample. Each lipid species was normalized by expressing
the signal as a proportion of the total signal for each participant.
Since the distributions of most of the lipid signals showed
approximate log-normality, natural log-transformation was then
applied to each normalized lipid signal. Lipid signals for
individual participants were considered outliers and excluded
if the normalized, log-transformed signal was more than 10
standard deviations (SD) from the mean for that lipid across all
participants. Since the majority of PROMIS participants were
not fasting at time of blood draw and their lipid levels could have
spiked if they had recently consumed a high-fat meal, 10-SD was
used as the cutoff to avoid being overly conservative. It is
unlikely that lipids would have true values more than 10-SD
from the mean, so any excluded measurements were either
below the lower limit of detection or the measurement was false,
perhaps due to a contaminant.
Principal Component Analysis
We used principal component analysis (PCA) to determine the
main differences in lipid profiles across the participants,
excluding 17 lipids (3.8%) with missing signal data in more
than 10% of participants. The matrix loadings were orthogonally
rotated and the first four principal components were retained
based on examination of the scree plot of the eigenvalues. We
produced scatter plots comparing the first versus second and
third versus fourth principal components, and investigated the
association (odds ratios and 95% confidence intervals [CIs]) of
these principal components with several established CHD risk
factorsoverweight, obesity, hypertension, and diabetes
which were defined using well-established cutoff points from
published guidelines.23−26
We also conducted genome-wide association analyses using
SNPTEST v2.4.127 for the association of these principal
components with over 6.7 million genetic variants. Each
principal component was adjusted for age group, sex, date of
survey, plate (batch), fasting status, and six principal
components from the multidimensional scaling matrix to
account for population stratification. Beta estimates and
standard errors from the association results from the two
genetic platforms were combined in a fixed-effect inverse-
variance-weighted meta-analysis using METAL (2011−03−
25).28
Principal components were also investigated in a subset of
triacylglycerols and a subset of lipids associated with rs662799 in
the APOA5−APOC3 region.
Journal of Proteome Research Article
DOI: 10.1021/acs.jproteome.8b00786
J. Proteome Res. XXXX, XXX, XXX−XXX
D
Assessment of Correlations between Lipids
The partial correlation of each phosphatidylcholine and
triacylglycerol with four major lipid markerstotal cholesterol,
HDL-C, LDL-C, and total triacylglycerolswas assessed with
adjustment for age and sex. To examine lipid cross-correlations
and distinguish between direct and indirect metabolic
interactions,29 we estimated a Gaussian Graphical Model
(GGM) on the normalized relative intensities of the lipids
using the “genenet” R package,30 which was performed between
each pair of lipids while keeping all other lipids constant. The
GGM resulted in a set of edges in which each edge connected
two detected lipids if their cross-correlation conditioned on all
other lipids was significantly different from zero. A similar
approach for metabolomics data has been suggested previ-
ously.29 We excluded 334 (6%) participants with missing signal
data in more than 10% of the lipids and 8 (2%) lipids with
missing signal data in more than 20% of the participants from the
GGM analysis. To focus on strong effects, we retained only
edges in the model that met an FDR cutoff of 0.05 and had a
partial correlation coefficient greater than 0.2. This resulted in a
network of the partial correlations between all lipids. The results
were summarized and combined within each lipid subclass to
produce a heat map of the partial correlations between each of
the lipid subclasses.
Fatty Acid Chain Enrichment Analysis
We manually annotated detected lipids with their constituent
fatty acid chains using the annotation data from the pooled
sample. For each combination of fatty acid chains, we counted
the number of GGM edges connecting lipids with that specific
combination, which we used to directly estimate P-values of
enrichment and depletion. To test whether edges from the
GGMwere enriched for any combination of fatty acid chains, we
permuted the annotation 1000 times using the “BiRewire” R
package,31 keeping the number of annotations per lipid and fatty
acid chain constant. We then produced a heat map of the partial
correlations between lipids based on their constituent fatty acid
chains.
Table 1. Demographic and Clinical Characteristics and Coronary Heart Disease Risk Factors of Individuals Assayed by DIHRMS
in PROMISa
PROMIS controls assayed by DIHRMS
(n = 5662) All PROMIS controls (n = 18 564) DHS Pakistan (n = 13 558)
variable no. of subjects mean (SD) or % no. of subjects mean (SD) or % no. of subjects mean (SD) or %
Anthropometric markers
Age at survey (yrs) 5662 54 (9) 18 564 56 (9) 13 558 33 (9)
Body-mass index (kg/m2) 5562 26 (5) 18 290 26 (5) 4698 25 (6)
Waist-to-hip ratio 5590 0.96 (0.13) 18 344 0.95 (0.06) − −
Systolic blood pressure (mm Hg) 5587 128 (17) 18 255 128 (17) − −
Diastolic blood pressure (mm Hg) 5584 81 (9) 18 247 81 (10) − −
Circulating lipid biomarkers
Total cholesterol (mmol/L) 5542 4.63 (1.33) 17 935 4.68 (1.30) − −
HDL cholesterol (mmol/L) 5530 0.89 (0.27) 17 881 0.93 (0.28) − −
LDL cholesterol (mmol/L) 5439 2.77 (1.03) 17 491 2.81 (1.01) − −
Non-HDL cholesterol (mmol/L) 5530 3.75 (1.31) 17 884 3.75 (1.27) − −
Loge triacylglycerides (mmol/L) 5537 0.74 (0.53) 17 920 0.69 (0.53) − −
Categorical variables
Sex 5662 18 564 13 558
Male 4466 79% 14 049 76% 12 409 92%
Female 1196 21% 4515 24% 1149 8%
Tobacco consumption status 5651 18 512 13 542
Current 1727 31% 5294 29% 1016 8%
History of diabetes 5651 18 516 −
Yes 780 14% 2435 13% − −
Diabetic drug use status 5654 18 540 −
Yes 561 10% 1847 10% − −
Antihypertensive drug use status 5655 18 539 −
Yes 909 16% 3308 18% − −
CHD risk factors
Overweight 5562 18 290 4698
Yes 3116 56% 10 460 57% 1891 40%
Obese 5562 18 290 4698
Yes 926 17% 2951 16% 667 14%
Hypertension 5587 18 257 −
Yes 987 18% 3240 18% − −
Diabetes 4212 8503 −
Yes 1612 38% 3003 35% − −
aDefinitions: Diabetes = HbA1c ≥ 6.5%; Hypertension = SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg; Obese = BMI ≥ 30 kg/m2; Overweight = BMI
≥ 25 kg/m2. Abbreviations: BMI, body mass index; CHD, coronary heart disease; DBP, diastolic blood pressure; DHS, Demographic and Health
Surveys; SBP, systolic blood pressure; SD, standard deviation. Note: Percentages may not add up to 100% due to rounding. Data for the overall
Pakistani population was obtained from the DHS. A dash (−) indicates that data were not available.
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Lipidome Scan of APOA5−APOC3 Region
In order to demonstrate the efficacy and potential utility of the
platform, a lipidome scan was conducted analyzing the
association of lipids with a common polymorphism (rs662799,
chr11:116663707) in the APOA5−APOC3 region known to be
associated with major lipid markers and CAD.13,14 Within each
overall lipid category, the lipid most strongly associated with
rs662799 was assessed for correlation with a wide range of major
lipids and other circulating biomarkers.
Analyses were performed using Stata v15.1 (StataCorp, 2017)
and R v3.3.2 (R Core Team, 2016) except where noted
otherwise. Two-sided P-values and 95% CIs are presented.
■ RESULTS
Description of the Study Population
Lipid profiles obtained using DIHRMS were available for 5662
PROMIS participants following data processing, cleaning, and
QC. Demographic and clinical characteristics of these
participants are shown in Table 1. The median age was 54
years (range: 27−87 years), the majority of participants (79%)
were male, and the average body mass index (BMI) was 26 kg/
m2 (range: 14−75 kg/m2). Although all participants in this
analysis were healthy controls at baseline, they represent a
population at increased risk of MI since 56% of the participants
were overweight, 17% were obese, 18% had hypertension, and
38% had diabetes. The subset of PROMIS controls selected for
the lipidomics assay were comparable to all PROMIS controls
(n = 18 564). However, based on nationwide survey data
obtained from the Demographic and Health Survey for
Pakistan,32 PROMIS participants were older on average, and a
higher proportion consumed tobacco and were overweight,
compared with the head of household in the general Pakistani
population (Table 1).
DIHRMS Is a Novel, High-Throughput Approach To Rapidly
and Accurately Profile Lipid Species
Our DIHRMS method for lipidomics covers a wide range of
lipids, including fatty acyls, glycerolipids, glycerophospholipids,
sphingolipids, and sterol lipids (Table 2), and does not require
prior selection of specific lipids or lipid classes if using the local
lipid database alone, in contrast to fragmentation-based
approaches using tandem mass spectrometry. The high-
throughput nature of the method means that with an analysis
time of just over 2 min per sample, it is possible to run a full plate
of 96 samples (including blanks and QC samples) within 4 h.
Importantly, the DIHRMS method included measurement of
neutral lipids such as triacylglycerols and cholesterol esters,
which are not covered by the commercial platforms that are
currently most widely used in large-scale metabolite phenotyp-
ing for genome-wide association studies (GWAS). As a result,
the measurements included approximately 125 metabolic
features that have not yet been assessed in any of the major
GWAS of human metabolism33 and lipids that contain odd-
chain fatty acids, which have generally been ignored in preceding
metabolic profiling efforts, despite their importance to human
health.34
DIHRMS Reveals Detailed Lipid Classes and Their
Correlation Structure
Following QC filtering, 207 lipids in positive ionization mode
and 238 lipids in negative ionizationmode remained for analysis,
all with unique mass-to-charge ratios and identifiers. When
allowing for species that were detectable as different adducts in
positive and negative mode, this equated to the detection of at
least 360 different lipid species (note that due to incomplete
assignment some peaks were assigned to more than one lipid
class). We also excluded 123 participants (2%) as part of the QC
process. The extent of missing data according to the number of
lipids and participants is shown in Figure S1 of the Supporting
Information. We found that 5328 out of 5662 participants
(94%) had complete information for at least 90% of the lipids
Table 2. Categorization of Lipids in Positive and Negative Ionization Mode Measured by Direct Infusion High-Resolution Mass
Spectrometry in PROMISa
overall lipid category lipid main class lipid subclass no. (%) of lipids
Fatty acyls (FA) Fatty acids and conjugates Free fatty acids (FreeFA) (−) 22 (5.0%)
Glycerolipids (GL) Diradylglycerols Diacylglycerols (DG) (+) 19 (4.3%)
Triradylglycerols Triacylglycerols (TG) (+) 56 (12.6%)
Glycerophospholipids (GP) Glycerophosphates Phosphatic acids (PA) (−) 20 (4.5%)
Phosphatic acids (PA) (+) 13 (2.9%)
Glycerophosphocholines Lysophosphocholines (LysoPC) (+) 8 (1.8%)
Phosphatidylcholines (PC) (−) 52 (11.7%)
Phosphatidylcholines (PC) (+) 54 (12.2%)
Glycerophosphoethanolamines Phosphatidylethanolamines (PE) (−) 24 (5.4%)
Phosphatidylethanolamines (PE) (+) 16 (3.6%)
Glycerophosphoglycerols Phosphatidylglycerols (PG) (−) 5 (1.1%)
Glycerophosphoinositols Phosphatidylinositols (PI) (−) 25 (5.6%)
Glycerophosphoserines Phosphatidylserines (PS) (−) 22 (5.0%)
Sphingolipids (SP) Ceramides Ceramides (Cer) (−) 16 (3.6%)
Phosphosphingolipids Sphingomyelins (SM) (−) 51 (11.5%)
Sphingomyelins (SM) (+) 27 (6.1%)
Sterol lipids (ST) Sterols Cholesterols and derivatives (Chol) (+) 2 (0.5%)
Cholesteryl esters (CE) (+) 12 (2.7%)
Total lipids 360
a(+) denotes lipids measured in positive ionization mode; (−) denotes lipids measured in negative ionization mode. Note the final total takes into
consideration the detection of some lipids in both positive and negative mode, multiple adducts, and the possibility of multiple annotations.
Journal of Proteome Research Article
DOI: 10.1021/acs.jproteome.8b00786
J. Proteome Res. XXXX, XXX, XXX−XXX
F
(Figure S1a), and 427 out of 444 lipids (96%) had less than 10%
(between 0 and 9%) missing data (i.e., were detected in at least
90% of the samples) (Figure S1b). The median coefficient of
variation (CV) was 11.60% (range: 5.4−51.9). The CVs for all
444 retained lipid signals are shown in Figure S2a. The precision
was higher in positive mode (median CV 11.48%) than in
negative mode (median CV 22.34%). However, the CVs
demonstrated that simple normalization yielded reproducible
data on a par with other high-throughput metabolic profiling
methods.35,36
A scatter plot showing the normalized relative intensities of all
the lipids according to their m/z, grouped by participant, is
shown in Figure S2b. The wide distribution of the signals across
certain lipids, such as cholesterol with loss of −OH, CE(18:2),
PC(34:2), and TG(52:2), suggests that the levels of these lipids
vary significantly across individuals, whereas the levels of other
lipids are more consistent.
While most lipids were correlated with levels of major lipid
markers, confirming the validity of the platform, the direction of
the correlation varied according to the structure of the individual
lipids. The partial correlation coefficients and 95% CIs for each
of the 106 phosphatidylcholines and 56 triacylglycerols with four
major lipid markers are shown in Figure S3. The majority of
phosphatidylcholines were positively correlated with HDL-C
and inversely correlated with total triacylglycerols, while there
were wide variations in the correlations of phosphatidylcholines
with total cholesterol and LDL-C. In contrast, the majority of
individual triacylglycerols were positively correlated with total
cholesterol and total triacylglycerols and negatively correlated
with HDL-C, but did not exhibit a significant correlation with
LDL-C.
For many of the individual triacylglycerols, as the number of
double bonds increased (i.e., the level of saturation decreased)
[e.g., from TG(48:1) to TG(48:2) to TG(48:3), or from
TG(50:1) to TG(50:2) to TG(50:3)], the magnitude of the
correlation with each of the major lipid markers increased. A
likely explanation from previous research in obese individuals is
that triacylglycerols in adipose tissue become enriched with
monounsaturated fatty acids.37
Gaussian Graphical Modeling Highlights 222 Correlated
Lipid Species
We applied a Gaussian graphical modeling (GGM) approach
that used partial correlations to determine if specific lipids were
still strongly correlated after adjusting for all other lipids (Figure
2a). This modeling had two aims: first, for QC, to identify lipids
with very high correlations, which were likely to be artifacts of
the method; and second, to find relevant correlations that
provided information on the biochemical relationship between
lipids. The first step in this process was to examine which partial
correlates may have arisen from isotopologues with very high
correlation coefficients and would be misassignments using our
database approach of M ions. From the 314 significant partial
correlates, there were ten correlations that were most likely
purely M + 1 isotopes (the same lipid that contains one 13C
isotope) of other lipid signals and four correlations that were
purely M + 2 isotopes (the same lipid that contains two 13C
isotopes), based on very high correlations (r > 0.997) and
correct isotope ratios. There were 26 correlations where theM +
1 isotope contributed considerably to the signal and four
correlations where theM+ 2 isotope contributed predominantly
to the signal. However, those signals also showed contributions
of different lipid signals, for which the correlations were not as
high (r < 0.997) or the isotope ratio was incorrect. We identified
36 correlations where the signals came from the same lipid in
both positive and negative ionization modes, and two sets of
lipids for which the signals overlapped, and the peak-picking
Figure 2.Heat map showing relationships between lipid subclasses and constituent fatty acid chains of lipids based on partial correlations derived using
Gaussian Graphical Modeling. These heat maps show the relationships between (a) lipid subclasses and (b) constituent fatty acid chains based on the
inferredGaussian GraphicalModel (GGM). The number in each cell shows the observed number of GGMedges connecting two lipids in subclasses or
constituent fatty acid chains specified on the x- and y-axes. The cells are colored red or blue according to whether the observed number of GGM edges
is more or less than expected due to chance alone, and a box is drawn around the cell if there is a significant difference between the numbers of observed
versus expected GGM edges.
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algorithm was unable to distinguish the signals. The remaining
222 significant correlations were taken forward for further
analysis (Figure 2b).
Principal Component Analysis Classifies Lipids
Next, we assessed the overall technical and biological differences
in the lipid signals using PCA.We retained the first four principal
components, which explained 55.1% of the variance in the
relative intensities of the lipids, based on examination of the
scree plot of the eigenvalues (Figure S5). Scatter plots of the
matrix loadings of the first versus second and third versus fourth
principal components are shown in Figure S6a. The individual
lipids are distinguished by color according to the overall lipid
category to which they belong.
The first principal component (which explained 31.8% of the
variance in the lipid levels) correlated with differences between
the positive and negative ionization modes. The dynamic range
of the negative mode data was more limited than the positive
mode data, and due to the lower ionization efficiency, the data
were more prone to ion suppression. These differences between
the ionization modes were amplified when the data were
expressed relative to total signal intensity.We therefore excluded
the first principal component from further data analysis.
The second component (which explained 11.7% of the
variance) was dominated by triacylglycerols containing shorter
Figure 3. Cross-correlations of circulating biomarkers with the lipids within each overall lipid category most strongly associated with rs662799 in the
APOA5−APOC3 locus. For the lipids within each overall lipid category that were most strongly associated with rs662799 (chr11:116663707) in the
APOA5−APOC3 region, the correlations of these lipids with a range of circulating biomarkers are shown. Analyses were adjusted for age and sex.
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and more saturated fatty acids, which had the highest positive
loadings, versus fatty acids (e.g., free linoleic acid) and
cholesterol esterified with polyunsaturated fatty acids [e.g.,
CE(18:2)], which had the strongest negative loadings. The third
component (which explained 6.9% of the variance) differ-
entiated saturated phosphatidylcholines [e.g., PC aa (32:0), PC
aa (34:0), PC aa (32:0)] from triacylglycerols containing longer,
unsaturated fatty acids [e.g., TG(54:5), TG(54:7), TG(56:7)].
The fourth component (which explained 4.8% of the variance)
differentiated the odd-chain fatty acid containing sphingomye-
lins [e.g., SM(39:1), SM(41:1), SM(37:1)] with the highest
positive loadings versus saturated free fatty acids and
triacylglycerols [e.g., TG(52:2), TG(54:2)] with the strongest
negative loadings.
Principal Component Analysis Stratifies Triacylglycerols by
Fatty Acid Chains
To provide a more detailed exploration of differences between
specific types of lipids, we also examined principal components
in a subset of lipids consisting of only triacylglycerols. The
corresponding scatter plots of these principal components are
shown in Figure S6b. The first principal component of the
triacylglycerols distinguished triacylglycerols with an odd
number of carbon atoms [e.g., TG(49:3), TG(51:4),
TG(55:9)], shown in the blue oval, from those with an even
number of carbon atoms [e.g., TG(50:0), TG(52:1),
TG(54:3)], shown in the green oval. Previous work has
shown that odd-chain fatty acids derive primarily from dairy
consumption, while even-chain fatty acids are either synthesized
in the liver through de novo lipogenesis or ingested through
consumption of saturated fatty foods.34,38,39
The second principal component differentiated triacylglycer-
ols with saturated and monounsaturated fatty acid chains [e.g.,
TG(44:1), TG(47:1), TG(49:2)], shown in the green and blue
ovals at the top of the figure, from triacylglycerols containingω-3
and ω-6 polyunsaturated fatty acids [e.g., TG(54:4), TG(58:9),
TG(57:10)], shown in the orange oval at the bottom of the
figure. An important source of these polyunsaturated fatty acids
is fish consumption.40 The two pink ovals represent one or more
categories that are distinct from dairy consumption, fish
consumption, and saturated fat, but further research is needed
to determine their biological significance.
We found that the third principal component primarily
distinguished triacylglycerols containing polyunsaturated fatty
acids from those containing saturated fatty acids. The
interpretation of the fourth principal component of the
triacylglycerols was not readily apparent.
Association Pattern of APOA5−APOC3 Genetic Variants,
Lipids, and Lifestyle Factors
To provide a case study demonstrating the viability of this
lipidomics platform with a well-known genetic region, principal
components were also examined in a subset of the lipids that
were s ignificant ly associated with the rs662799
(chr11:116663707) variant in the APOA5−APOC3 gene at P
< 8.9 × 10−10. The scatter plots of these principal components
are shown in Figure S6c. The first principal component was
driven by relative increases in sphingomyelins and decreases in
cholesterol esters and triacylglycerols containing unsaturated
fatty acids. The second, third, and fourth principal components
were very effective at differentiating glycerolipids (i.e.,
diacylglycerols and triacylglycerols) from the other lipid classes.
As shown in Figure S4, out of the lipids that were significantly
associated with the APOA5−APOC3 variant, a number of lipids
had significantly positive associations with smoking and physical
activity, while other lipids had significant inverse associations
(the top 20 lipids most significantly associated with each
outcome are shown in the figure). A previous study41 showed
that two lipid subclasses (phosphocholines and phosphoetha-
nolamines) and 72 individual lipid species are associated with
smoking statusour study confirmed many of these associa-
tions. Smoking was associated with increased levels of TG(52:2)
and decreased levels of TG(52:4), which might suggest that
smoking oxidizes unsaturated fatty acids since the latter is more
unsaturated. Similar patterns in lipids with differing directions of
effect were observed for the association with physical activity,
although the majority of the associations were not statistically
significant.
Correlation of Lipids with Circulating Biomarkers Relevant
to CHD
For the lipids within each overall lipid category that were most
strongly associated with the APOA5−APOC3 variant [i.e.,
FreeFA(24:0)-H− (m/z 367.3582) for fatty acids, TG(53:3)
(m/z 888.8016) for glycerolipids, PC-O(39:3) or PC-P(39:2)
(m/z 812.6532) for glycerophospholipids, SM(42:3) (m/z
811.6688) for sphingolipids, and CE(20:3) (m/z 692.6339) for
sterol lipids], the cross-correlation of each lipid metabolite with
a wide range of clinical measurements, representing major lipid
Figure 4.Association of lipids with obesity, hypertension, and diabetes. All analyses were adjusted for age and sex. Out of the lipids that were associated
with rs662799 in the APOA5−APOC3 locus, results are shown for (a) the top 20 lipids that were most significantly associated with obesity, (b) the top
20 lipids that were most significantly associated with hypertension, and (c) the top 20 lipids that were most significantly associated with diabetes.
Definitions: Diabetes =HbA1c≥ 6.5%;Hypertension = SBP≥ 140mmHg or DBP≥ 90mmHg;Obese = BMI≥ 30 kg/m2. Abbreviations: BMI, body
mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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markers and other circulating biomarkers, was determined
(Figure 3a−e).
FreeFA(24:0)-H− was inversely associated with total
cholesterol, non-HDL cholesterol, LDL-C, triacylglycerols,
ApoB, ApoC3, ApoE, and several other biomarkers (Figure
3a). Triacylglycerol TG(53:3) (Figure 3b) showed significant
positive correlations with levels of total triacylglycerols, as would
be expected, but also with ApoB, ApoC3, and ApoE, total
cholesterol, non-HDL cholesterol, and several other biomarkers.
This triacylglycerol species also exhibited a significant negative
correlation with HDL-C and ApoA1. For the sphingolipid
[SM(42:3)] (Figure 3d) and sterol lipid [CE(20:3)] (Figure
3e), the strongest inverse associations were found with total
triacylglycerols, ApoC3, and ApoE. SM(42:3) had the strongest
correlation with HDL-C, while CE(20:3) had the strongest
correlation with LDL-C.
Association of Lipids with Various Risk Factors for CHD
The associations of lipid principal components with CHD risk
factors are shown in Figure S7. Individuals who were overweight
or diabetici.e., with high levels of CHD risk factorswere
more likely to have lipid profiles similar to those corresponding
to positive loadings in the second principal component. In
contrast, individuals who were not overweight or diabetic and
did not have hypertensioni.e., at reduced risk of CHDwere
more likely to have lipid profiles matching positive scores in the
third or fourth principal components. For example, a 1-SD
increase in the loading scores of the lipids that made up the third
principal component resulted in a 20% reduction in the risk of
being overweight (OR = 0.80, 95% CI 0.76−0.84) and a 23%
reduced risk of having diabetes according to levels of HbA1c (OR
= 0.77, 95% CI 0.72−0.81), which is a reflection of long-term
blood glucose levels.
Again using the subset of lipids that were significantly
associated with the APOA5−APOC3 variant, we also examined
the association of the top 20 lipids with the strongest
associations with obesity, hypertension, and diabetes (Figure
4). We found that individuals with elevated levels of almost all of
these diacylglycerols and triacylglycerols were very likely to have
obesity, hypertension, and diabetes, while the majority of
sphingomyelins, phosphocholines, and cholesterol esters were
predominantly inversely associated with these outcomes. One
exception is SM(38:1) (m/z 759.6372), which was positively
associated with obesity but inversely associated with hyper-
tension. However, it is important to note that there was no
follow-up of the participants in this study and we cannot
therefore directly determine associations between lipids and
CHD risk; we can only determine associations between lipids
and known CHD risk factors.
GWAS of Principal Components Derived from Lipid
Measurements
Finally, we conducted a GWAS of the second, third, and fourth
principal components derived from the lipids measured using
DIHRMS (Figure S8 and Table S1 in Supporting Information).
We identified 74 unique variants from two loci (APOA5−
APOC3 and FADS1−2−3) that reached genome-wide signifi-
cance (P < 5× 10−8). The second principal component was only
associated with a single variant from theAPOA5−APOC3 region
(rs662799), the third principal component was associated with
22 variants from the APOA5−APOC3 region, and the fourth
principal component was associated with 74 variants from both
loci.
Varied Genetic Associations of Lipids with APOA5−APOC3
Gene Region
The association of each individual lipid with a common
polymorphism (rs662799) in the APOA5−APOC3 cluster
revealed differences in the magnitude and direction of the
association according to overall lipid category (Figure 5). The
four glycerolipids (diacylglycerols and triacylglycerols) had
inverse associations with the effect allele for his variant, while the
cholesterol esters, phosphatidylcholines, sphingomyelins, and
cholesterol had positive associations.
■ DISCUSSION
In this study, we employed DIHRMS in combination with a
novel peak-picking algorithm to measure and characterize
approximately 360 lipids in 5662 participants from PROMIS.
Our robust approach has three major practical advantages: (1)
The automated sample preparation of one plate is possible in 1.5
h, making this approach applicable to large-scale lipid profiling;
(2) the method is extremely fast, so that with an analysis time of
just over 2 min per sample it is possible to run several hundred
samples per day; (3) as a consequence of the high throughput,
the cost per sample is greatly reduced; and (4) by virtue of the
simplicity of the method it is also robust, with low CVs
achievable for many of the lipid species detected. Moreover, the
two-dimensional nature of the DIHRMS data limits the need for
data alignment algorithms, which are necessary for three-
dimensional data such as those generated using LC-based
approaches.7 A slight disadvantage is that the use of high-
resolution mass spectrometry alone complicates species
identification compared to fragmentation-based approaches.17
However, the automated approach and rapid analysis speed
opens up the possibility of applying this method to much larger
epidemiological studies than was previously possible.17,18
Our determination of the correlation of each phosphatidyl-
choline and triacylglycerol with major lipid markers demon-
Figure 5. Association of the top 20 most significantly associated lipids
with rs662799 in the APOA5−APOC3 locus. Note: *P < 0.001; **P < 5
× 10−8; ***P < 8.9 × 10−10.
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strated distinct differences between individual lipids and their
relation to lipid markers measured using clinical chemistry (e.g.,
total cholesterol, total triacylglycerols, LDL-C, HDL-C).
Likewise, the GGM indicated that there were significantly
more correlations between lipids of the same subclass and lipids
with the same constituent fatty acids than would be expected
due to chance alone.
From the results of the overall PCA, the second principal
component revealed a contrast between free fatty acid levels
versus small, saturated triacylglycerols. Several factors could
have contributed to this differentiation. Volunteers were
recruited at different hospitals and blood samples were taken
directly after consent. Thus, there was significant variation in the
time since participants had eaten their last meal, which would
have strongly affected both the free fatty acid and triacylglycerol
pool content in blood plasma through the activity of lipases
acting on both blood and adipose tissue triacylglycerols. These
enzymes are in part regulated by insulin, thus influencing the
association between the second principal component and
increased risk of being overweight or diabetic. Because
physiological status also influences lipase activities, this could
have obscured the genetic associations, with only one SNP
demonstrating a genome-wide significant association with the
second principal component. Genetic variants in the APOA5−
APOC3 region have been associated with type 2 diabetes,42 fatty
liver disease,43 hypertriacylglycerolmia,44,45 and dyslipidae-
mia,46 and associated with metabolites such as 1-linoleoylglycer-
ol in previous metabolomics studies.47 However, as only one
variant was significantly associated with the second principal
component compared to 74 variants that were associated with
the third and fourth principal components, this suggests that the
second principal component was largely driven by dietary and
physiological patterns rather than genetic differences.
Although the third principal component was most closely
characterized by unsaturated triacylglycerols, it did not show any
significant associations with genetic variants in the FADS1−2−3
locus, and was only associated with variants in the APOA5−
APOC3 region. In contrast, variants in both the FADS1−2−3
and APOA5−APOC3 regions were significantly associated with
the fourth principal component. The loadings of the fourth
principal component showed that the triacylglycerols containing
linoleic acid (18:2), as well as linoleic acid as a free fatty acid, had
negative loading scores, while sphingomyelins containing odd-
chain fatty acids and desaturated phospholipids had positive
loading scores. The association between SNPs within the
FADS1−2−3 region with sphingomyelins has been described
previously,48 although not explained, and has not previously
been described for odd-chain fatty acid-containing sphingo-
myelins. The effect on the triacylglycerols also explained the
association with SNPs in the APOA5−APOC3 locus for the
fourth principal component. Both the third and fourth principal
components showed inverse associations with the relative risk
for being overweight and having diabetes, while only the fourth
principal component also showed an inverse association with the
relative risk for hypertension. This last observation is striking as
sphingomyelins have thus far been implicated in hypertension as
precursors to ceramide production, but odd-chain fatty acid-
containing sphingomyelins have mostly been unexplored, and in
the present study sphingolipid metabolism was associated with
perceived positive outcomes in terms of common clinical
chemistry measures, including inverse associations with total
triacylglycerols, ApoC3, ApoE, total cholesterol, and HbA1c, and
a positive association with HDL-C.
Our results from this study complement previous studies that
have examined the role of lipids in predicting levels of CVD risk
factors and determining risk of CVD. A tandem mass
spectrometry-based approach for targeted lipidomics has
demonstrated the predictive nature of the approach for general
anthropometric characteristics41 and both cardiovascular events
and death.49 An analysis of 310 lipid species detected in blood
plasma from the Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR-Controlled Evaluation (AD-
VANCE) trial found that the addition of seven lipid species to
a base model consisting of fourteen traditional risk factors and
medications to predict cardiovascular events increased the
C-index from 0.680 (95% CI 0.678−0.682) to 0.700 (95% CI
0.698−0.702; P < 0.0001).49 The prediction of cardiovascular
death was similarly improved by the inclusion of four lipid
species into the base model.49
Evidence strongly supports that proteins in the APOA5−
APOC3 region modulate lipoprotein lipase function and
influence liver uptake of remnants, leading to elevated
triacylglycerol levels and increased risk of CHD.14,50 However,
the details of which specific triacylglycerols, or indeed other lipid
species, are influenced by APOA5−APOC3 activity has not been
thoroughly understood. The lipidome scan of a common
polymorphism in the APOA5−APOC3 region revealed that
differences in apolipoprotein metabolism lead to several specific
changes in the lipid profile. In particular, increased APOA5−
APOC3 activity leads to decreases in levels of specific
triacylglycerols, mainly those containing monounsaturated
fatty acids. These findings highlight the opportunities of this
approach in larger studies, which can include sufficient coverage
of rare genetic variants, to help understand how polymorphisms
in APOA5−APOC3 can lead to changes in triacylglycerol levels.
Increased activity of theAPOA5−APOC3 variant also resulted in
increased concentrations of cholesterol esters, sphingomyelins,
and phosphatidylcholines, which suggests that variants in the
APOA5−APOC3 locus have a nonspecific effect on all lipid
classes.
A full genome-wide association analysis for each lipid,
investigation of novel loci, and identification of lipids that may
have a causal effect on risk of CHD was beyond the scope of the
present study. However, future work resulting from this
lipidomics platform will focus on a GWAS of each of the
individual lipids and the subsequent identification of novel
associations of lipids with CHD-related loci. While the present
study was cross-sectional in nature, we will also explore
opportunities to replicate these analyses in prospective cohort
studies, which have the opportunity to follow up participants
and assess the role of lipid metabolism in disease onset.
■ CONCLUSIONS
We show that fast, reproducible, and detailed lipid profiling is
possible on very large data sets, revealing that lipid profiles are
influenced by physiological, lifestyle, and genetic factors. This
lipidomics platform, then, is a useful tool that may prove
valuable to identify lipids that could become new biomarkers
used for clinical application in areas such as CHD screening,51
risk prediction,52 and drug development.53
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